Increased release and activity of matrix metalloproteinase-9 in patients with mandibuloacral dysplasia type A, a rare premature ageing syndrome

F. Lombardi, G. F. Fasciglione, M. R. D'Apice, A. Vielle, M. D'Adamo, P. Sbraccia, S. Marini, P. Borgiani, M. Coletta, Giuseppe Novelli

Research output: Contribution to journalArticle

Abstract

Mandibuloacral dysplasia type A (MADA; OMIM 248370), a rare disorder caused by mutation in the LMNA gene, is characterized by post-natal growth retardation, craniofacial and skeletal anomalies (mandibular and clavicular hypoplasia, acroosteolysis, delayed closure of cranial sutures, low bone mass and joint contractures), cutaneous changes and partial lipodystrophy. Little is known about the molecular mechanisms by which LMNA mutations produce bone alterations. An altered bone extracellular matrix (ECM) remodelling could play a pivotal role in this disorder and influence part of the typical bone phenotype observed in patients. Therefore, we have focused our investigation on matrix metalloproteinases (MMPs), which are degradative enzymes involved in ECM degradation and ECM remodelling, thus likely contributing to the altered bone mineral density and bone metabolism values seen in five MADA patients. We evaluated the serum levels of several MMPs involved in bone development, remodelling and homeostasis, such as MMP-9, -2, -3, -8 and -13, and found that only the 82 kDa active enzyme forms of MMP-9 are significantly higher in MADA sera compared with healthy controls (n = 16). The serum level of MMP-3 was instead lower in all patients. No significant differences were observed between controls and MADA patients for the serum levels of MMP-2, -8 and -13 and of tissue inhibitor of metalloproteinase 2, a natural inhibitor of MMP-9. Similarly, normal serum levels of tumour necrosis factor alpha (TNF-α), interleukin (IL)-6 and IL-1β were detected. These data suggest a possible involvement of MMP-9 in MADA disease, underlying the potential use in diagnosis and therapy.

Original languageEnglish
Pages (from-to)374-383
Number of pages10
JournalClinical Genetics
Volume74
Issue number4
DOIs
Publication statusPublished - 2008

Fingerprint

Premature Aging
Matrix Metalloproteinase 9
Extracellular Matrix
Bone and Bones
Serum
Matrix Metalloproteinase 2
Matrix Metalloproteinases
Acro-Osteolysis
Cranial Sutures
Matrix Metalloproteinase 8
Genetic Databases
Lipodystrophy
Tissue Inhibitor of Metalloproteinase-2
Matrix Metalloproteinase 3
Mutation
Bone Matrix
Bone Remodeling
Bone Development
Contracture
Enzymes

Keywords

  • Bone remodelling
  • Laminopathies
  • Mandibuloacral dysplasia
  • MMPs

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Increased release and activity of matrix metalloproteinase-9 in patients with mandibuloacral dysplasia type A, a rare premature ageing syndrome. / Lombardi, F.; Fasciglione, G. F.; D'Apice, M. R.; Vielle, A.; D'Adamo, M.; Sbraccia, P.; Marini, S.; Borgiani, P.; Coletta, M.; Novelli, Giuseppe.

In: Clinical Genetics, Vol. 74, No. 4, 2008, p. 374-383.

Research output: Contribution to journalArticle

Lombardi, F, Fasciglione, GF, D'Apice, MR, Vielle, A, D'Adamo, M, Sbraccia, P, Marini, S, Borgiani, P, Coletta, M & Novelli, G 2008, 'Increased release and activity of matrix metalloproteinase-9 in patients with mandibuloacral dysplasia type A, a rare premature ageing syndrome', Clinical Genetics, vol. 74, no. 4, pp. 374-383. https://doi.org/10.1111/j.1399-0004.2008.01034.x
Lombardi, F. ; Fasciglione, G. F. ; D'Apice, M. R. ; Vielle, A. ; D'Adamo, M. ; Sbraccia, P. ; Marini, S. ; Borgiani, P. ; Coletta, M. ; Novelli, Giuseppe. / Increased release and activity of matrix metalloproteinase-9 in patients with mandibuloacral dysplasia type A, a rare premature ageing syndrome. In: Clinical Genetics. 2008 ; Vol. 74, No. 4. pp. 374-383.
@article{d962476c6a484194b0f2b9b20d0f6a9e,
title = "Increased release and activity of matrix metalloproteinase-9 in patients with mandibuloacral dysplasia type A, a rare premature ageing syndrome",
abstract = "Mandibuloacral dysplasia type A (MADA; OMIM 248370), a rare disorder caused by mutation in the LMNA gene, is characterized by post-natal growth retardation, craniofacial and skeletal anomalies (mandibular and clavicular hypoplasia, acroosteolysis, delayed closure of cranial sutures, low bone mass and joint contractures), cutaneous changes and partial lipodystrophy. Little is known about the molecular mechanisms by which LMNA mutations produce bone alterations. An altered bone extracellular matrix (ECM) remodelling could play a pivotal role in this disorder and influence part of the typical bone phenotype observed in patients. Therefore, we have focused our investigation on matrix metalloproteinases (MMPs), which are degradative enzymes involved in ECM degradation and ECM remodelling, thus likely contributing to the altered bone mineral density and bone metabolism values seen in five MADA patients. We evaluated the serum levels of several MMPs involved in bone development, remodelling and homeostasis, such as MMP-9, -2, -3, -8 and -13, and found that only the 82 kDa active enzyme forms of MMP-9 are significantly higher in MADA sera compared with healthy controls (n = 16). The serum level of MMP-3 was instead lower in all patients. No significant differences were observed between controls and MADA patients for the serum levels of MMP-2, -8 and -13 and of tissue inhibitor of metalloproteinase 2, a natural inhibitor of MMP-9. Similarly, normal serum levels of tumour necrosis factor alpha (TNF-α), interleukin (IL)-6 and IL-1β were detected. These data suggest a possible involvement of MMP-9 in MADA disease, underlying the potential use in diagnosis and therapy.",
keywords = "Bone remodelling, Laminopathies, Mandibuloacral dysplasia, MMPs",
author = "F. Lombardi and Fasciglione, {G. F.} and D'Apice, {M. R.} and A. Vielle and M. D'Adamo and P. Sbraccia and S. Marini and P. Borgiani and M. Coletta and Giuseppe Novelli",
year = "2008",
doi = "10.1111/j.1399-0004.2008.01034.x",
language = "English",
volume = "74",
pages = "374--383",
journal = "Clinical Genetics",
issn = "0009-9163",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "4",

}

TY - JOUR

T1 - Increased release and activity of matrix metalloproteinase-9 in patients with mandibuloacral dysplasia type A, a rare premature ageing syndrome

AU - Lombardi, F.

AU - Fasciglione, G. F.

AU - D'Apice, M. R.

AU - Vielle, A.

AU - D'Adamo, M.

AU - Sbraccia, P.

AU - Marini, S.

AU - Borgiani, P.

AU - Coletta, M.

AU - Novelli, Giuseppe

PY - 2008

Y1 - 2008

N2 - Mandibuloacral dysplasia type A (MADA; OMIM 248370), a rare disorder caused by mutation in the LMNA gene, is characterized by post-natal growth retardation, craniofacial and skeletal anomalies (mandibular and clavicular hypoplasia, acroosteolysis, delayed closure of cranial sutures, low bone mass and joint contractures), cutaneous changes and partial lipodystrophy. Little is known about the molecular mechanisms by which LMNA mutations produce bone alterations. An altered bone extracellular matrix (ECM) remodelling could play a pivotal role in this disorder and influence part of the typical bone phenotype observed in patients. Therefore, we have focused our investigation on matrix metalloproteinases (MMPs), which are degradative enzymes involved in ECM degradation and ECM remodelling, thus likely contributing to the altered bone mineral density and bone metabolism values seen in five MADA patients. We evaluated the serum levels of several MMPs involved in bone development, remodelling and homeostasis, such as MMP-9, -2, -3, -8 and -13, and found that only the 82 kDa active enzyme forms of MMP-9 are significantly higher in MADA sera compared with healthy controls (n = 16). The serum level of MMP-3 was instead lower in all patients. No significant differences were observed between controls and MADA patients for the serum levels of MMP-2, -8 and -13 and of tissue inhibitor of metalloproteinase 2, a natural inhibitor of MMP-9. Similarly, normal serum levels of tumour necrosis factor alpha (TNF-α), interleukin (IL)-6 and IL-1β were detected. These data suggest a possible involvement of MMP-9 in MADA disease, underlying the potential use in diagnosis and therapy.

AB - Mandibuloacral dysplasia type A (MADA; OMIM 248370), a rare disorder caused by mutation in the LMNA gene, is characterized by post-natal growth retardation, craniofacial and skeletal anomalies (mandibular and clavicular hypoplasia, acroosteolysis, delayed closure of cranial sutures, low bone mass and joint contractures), cutaneous changes and partial lipodystrophy. Little is known about the molecular mechanisms by which LMNA mutations produce bone alterations. An altered bone extracellular matrix (ECM) remodelling could play a pivotal role in this disorder and influence part of the typical bone phenotype observed in patients. Therefore, we have focused our investigation on matrix metalloproteinases (MMPs), which are degradative enzymes involved in ECM degradation and ECM remodelling, thus likely contributing to the altered bone mineral density and bone metabolism values seen in five MADA patients. We evaluated the serum levels of several MMPs involved in bone development, remodelling and homeostasis, such as MMP-9, -2, -3, -8 and -13, and found that only the 82 kDa active enzyme forms of MMP-9 are significantly higher in MADA sera compared with healthy controls (n = 16). The serum level of MMP-3 was instead lower in all patients. No significant differences were observed between controls and MADA patients for the serum levels of MMP-2, -8 and -13 and of tissue inhibitor of metalloproteinase 2, a natural inhibitor of MMP-9. Similarly, normal serum levels of tumour necrosis factor alpha (TNF-α), interleukin (IL)-6 and IL-1β were detected. These data suggest a possible involvement of MMP-9 in MADA disease, underlying the potential use in diagnosis and therapy.

KW - Bone remodelling

KW - Laminopathies

KW - Mandibuloacral dysplasia

KW - MMPs

UR - http://www.scopus.com/inward/record.url?scp=52449133616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52449133616&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0004.2008.01034.x

DO - 10.1111/j.1399-0004.2008.01034.x

M3 - Article

C2 - 18554282

AN - SCOPUS:52449133616

VL - 74

SP - 374

EP - 383

JO - Clinical Genetics

JF - Clinical Genetics

SN - 0009-9163

IS - 4

ER -